Dichotomy of AML1-ETO functions: Growth arrest versus block of differentiation

Molecular and Cellular Biology

Volumn 21, Issue 16, 2001, Pages 5577-5590

  Burel, S A ^a   Harakawa, N ^a   Zhou, L ^a   Pabst, T ^a   Tenen, D G ^a   Zhang, D E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CYCLIN DEPENDENT KINASE 4; PROTEIN BCL 2; TETRACYCLINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CORRELATION FUNCTION; DOWN REGULATION; GENE AML1 ETO; GENE EXPRESSION; GENE FUSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID; ONCOGENE PROTEINS, FUSION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034941566     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.16.5577-5590.2001     Document Type: Article

References (78)

1. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO
2. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults
3. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis
4. Diminished cell proliferation associated with the death-protective activity of Bcl-2
5. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse
6. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells
7. BCL-2 family: Regulators of cell death
8. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance
9. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1
10. Leukemogenesis by CBF oncoproteins
11. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family
12. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
13. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
14. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
15. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
16. Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11
17. Versatile retroviral vectors for potential use in gene therapy
18. Identification of CDK4 as a target of c-MYC
19. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene
20. Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha
21. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus
22. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1
23. The AML1/ETO fusion protein activates transcription of BCL-2
24. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2
25. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies
26. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia
27. Biological role of the CCAAT/Enhancer-binding protein family of transcription factors
28. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation
29. 1 progression in hematopoietic cells expressing a dominant-negative CBF - A model for overcoming inhibition of proliferation by CBF oncoproteins
30. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation
31. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein
32. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors
33. Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death
34. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
35. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions
36. Preparation of mouse cell suspensions
37. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia
38. Identification of a p53-dependent negative response element in the bcl-2 gene
39. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
40. t(8:21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1
41. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
42. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1
43. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis
44. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
45. C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter
46. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha
47. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
48. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
49. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry
50. AML1-ETO down-regulates the granulocytic differentiation factor C/EBP-α in t(8;21) myeloid leukemia
51. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia
52. Multiple functional domains of AML1: PU.1 and C/EBPα synergize with different regions of AML1
53. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors
54. Bcl-2 family proteins
55. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
56. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
57. Low BCL-2 expression in acute leukemia with t(8;21) chromosomal abnormality
58. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the upregulation of CCAAT/enhancer binding protein epsilon
59. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
60. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells
61. Core-binding factor: A central player in hematopoiesis and leukemia
62. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle
63. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents
64. CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein
65. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
66. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells
67. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis
68. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers
69. C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts
70. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia
71. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-α, inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation
72. C/EBPepsilon is a myeloid-specific activator of cytokine, chemokine, and macrophage-colony-stimulating factor receptor genes
73. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice
74. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing
75. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
76. Regulation of CD14 expression during monocytic differentiation induced with 1 alpha,25-dihydroxyvitamin D3
77. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter
78. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice